People · Operator
Named in public records as an officer, director or promoter · active 2020–2020 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Novosteo Inc. | — | Pharmaceuticals | Series B | $17.7M | $494.7M | 2020 |
Dan S. Hasler at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Dan S. Hasler on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| William J. Rutter | 1 | 3 |
| David J. Lamond | 1 | 1 |
| Daniel S. Hasler | 1 | 1 |
| Dirk Thye, M.D. | 1 | 1 |
| Alex S. Andrianopoulos | 1 | 1 |
| Philip S. Low, Ph.D. | 1 | 1 |
| Martin S. Brena, Ph.D. | 1 | 1 |
| William J. Boyle, Ph.D. | 1 | 1 |
| Stewart A. Low, Ph.D. | 1 | 1 |
| Pascal S. Krotee | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.